Cancer Institute A national cancer institute
designated cancer center

Matthew Bogyo

Publication Details

  • Proteasome inhibitors: Complex tools for a complex enzyme PROTEASOME-UBIQUITIN PROTEIN DEGRADATION PATHWAY Bogyo, M., Wang, E. W. 2002; 268: 185-208


    As the dominant protease dedicated to protein turnover, the proteasome shapes the cellular protein repertoire. Our knowledge of proteasome regulation and activity has improved considerably over the past decade. Novel inhibitors, in particular, have helped to advance our understanding of proteasome biology. They range from small peptide-based structures that can be modified to vary target specificity, to large macromolecular inhibitors that include proteins. While these reagents have played an important role in establishing our current knowledge of the proteasome's catalytic mechanism, many questions remain. Rapid advances in the synthesis and identification of new classes of proteasome inhibitors over the last 10 years serve as a positive indicator that many of these questions will soon be resolved. The future lies in designing compounds that can function as drugs to target processes involved in disease progression. It may only be a short while before the products of such research have safe application in a practical setting. Structural and combinatorial chemistry approaches are powerful techniques that will bring us closer to these goals.

    View details for Web of Science ID 000176957700008

    View details for PubMedID 12083006

Stanford Medicine Resources:

Footer Links: